References
- Kow CS, Hasan SS. Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic. Expert Rev Cardiovasc Ther. Online ahead of print. 2020:1–2. DOI:10.1080/14779072.2021.1842050
- Bottino LG, Fuchs FD. The role of angiotensin receptor blockers in CVD risk management. Expert Rev Cardiovasc Ther. 2020;18(4):181–185.
- Bangalore S, Kumar S, Wetterslev J, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.
- Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–2051.
- Fuchs FD, Scala LC, Vilela-Martin JF, et al. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-Treatment randomized trial. J Hypertens. 2016;34(4):798–806.
- Fuchs FD, Scala LCN, Vilela-Martin JF, et al. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. Acta Diabetol. 2020. Online ahead of print. DOI: 10.1007/s00592-020-01611-8
- Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med. 2013;18(2):44–47.
- Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–292.
- Ferdinand KC, Izzo JL, Lee J, et al. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation. 2019;139(18):2098–2109.
- ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.